We are live on ! Find out more
USNA icon

Usana Health Sciences

188 hedge funds and large institutions have $1.13B invested in Usana Health Sciences in 2021 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 62 increasing their positions, 71 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

1% more capital invested

Capital invested by funds: $1.12B → $1.13B (+$12.6M)

0.49% less ownership

Funds ownership: 55.29%54.8% (-0.49%)

5% less funds holding

Funds holding: 198188 (-10)

13% less repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 71

36% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 25

53% less call options, than puts

Call options by funds: $614K | Put options by funds: $1.31M

Holders
188
Holders Change
-10
Holders Change %
-5.05%
% of All Funds
3.27%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
16
Increased
62
Reduced
71
Closed
25
Calls
$614K
Puts
$1.31M
Net Calls
-$697K
Net Calls Change
-$259K
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$192M -$5.95M -59,283 -3%
Renaissance Technologies
2
Renaissance Technologies
New York
$158M -$2.27M -22,600 -1%
Vanguard Group
3
Vanguard Group
Pennsylvania
$153M -$317K -3,154 -0.2%
Acadian Asset Management
4
Acadian Asset Management
Massachusetts
$75.6M -$776K -7,726 -1%
Dimensional Fund Advisors
5
Dimensional Fund Advisors
Texas
$59.2M -$1.59M -15,788 -3%
State Street
6
State Street
Massachusetts
$38.4M +$1.28M +12,701 +4%
Wellington Management Group
7
Wellington Management Group
Massachusetts
$35.9M +$4.26M +42,401 +14%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$22.3M +$1.36M +13,511 +7%
D.E. Shaw & Co
9
D.E. Shaw & Co
New York
$21.9M -$887K -8,836 -4%
Arrowstreet Capital
10
Arrowstreet Capital
Massachusetts
$18.6M -$4.36M -43,453 -19%
Invesco
11
Invesco
Georgia
$16.9M +$10M +99,993 +155%
N
12
Nuveen
North Carolina
$16.5M -$1.07M -10,667 -6%
Northern Trust
13
Northern Trust
Illinois
$15.4M +$158K +1,573 +1%
Charles Schwab
14
Charles Schwab
California
$13.5M +$628K +6,251 +5%
Man Group
15
Man Group
United Kingdom
$13.4M -$8.48M -84,441 -39%
Bank of New York Mellon
16
Bank of New York Mellon
New York
$13.4M -$516K -5,140 -4%
Norges Bank
17
Norges Bank
Norway
$12.3M -$1.65M -16,386 -12%
Russell Investments Group
18
Russell Investments Group
United Kingdom
$12.2M -$1.58M -15,730 -12%
Principal Financial Group
19
Principal Financial Group
Iowa
$9.48M -$546K -5,438 -6%
JP Morgan Chase
20
JP Morgan Chase
New York
$9.11M +$4.26M +42,457 +91%
Prudential Financial
21
Prudential Financial
New Jersey
$8.76M -$4.75M -47,335 -36%
Deutsche Bank
22
Deutsche Bank
Germany
$8.51M -$251K -2,503 -3%
Nordea Investment Management
23
Nordea Investment Management
Sweden
$8.17M +$749K +7,458 +10%
Morgan Stanley
24
Morgan Stanley
New York
$8.14M -$1.47M -14,594 -16%
Goldman Sachs
25
Goldman Sachs
New York
$7.82M -$1.45M -14,461 -16%

USNA Hedge Fund Activity: Q2 2021 in Review

188 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Usana Health Sciences (USNA) for Q2 2021, worth a combined $1.13B — up 1.1% from $1.12B a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of USNA and 16 opened new positions — a net loss of 9 holders — while 71 trimmed existing stakes and 62 added.

The largest buyer was Invesco, adding an estimated $10M. The largest seller was CAAS Capital Management, exiting entirely with an estimated $13.8M sold.

  • 188 institutional investors held Usana Health Sciences (USNA) as of Q2 2021, down from 198 in Q1 2021.
  • Funds reported $1.13B of Usana Health Sciences stock for Q2 2021, up 1.1% quarter-over-quarter.
  • 16 funds opened new Usana Health Sciences positions in Q2 2021 and 25 closed out, a net change of -9 holders.
  • The largest Usana Health Sciences buyer in Q2 2021 was Invesco, an estimated $10M added.
  • The largest Usana Health Sciences seller in Q2 2021 was CAAS Capital Management, an estimated $13.8M sold.

Based on aggregated 13F filings for Q2 2021.